News in brief - May 2013

Other new launches, licence changes and prescribing updates relevant to general practice.

The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
  • A generic equivalent of Malarone (atovaquone/proguanil) has been launched for the prophylaxis and treatment of acute uncomplicated P. falciparum malaria.
  • The antidiabetic combination tablet Komboglyze (metformin/saxagliptin) is now indicated for use in combination with a sulfonylurea when a sulfonylurea plus metformin is inadequate.
  • A licensed oral suspension of clobazam, Tapclob, has been launched for use as an adjunct in epilepsy.
  • Isentress (raltegravir) is now available as chewable tablets to treat HIV-1 infection in children from the age of 2 years.
  • The cannabis-based MS spasticity treatment Sativex has been reclassified as a Schedule 4 CD, meaning that it can now be prescribed as a POM without any restrictions.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases